Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Sci Rep ; 12(1): 1777, 2022 02 02.
Article in English | MEDLINE | ID: mdl-35110610

ABSTRACT

Lobar selective internal radiation therapy (SIRT) is widely used to treat liver tumors inducing atrophy of the treated lobe and contralateral hypertrophy. The lack of animal model has precluded further investigations to improve this treatment. We developed an animal model of liver damage and atrophy-hypertrophy complex after SIRT. Three groups of 5-8 rabbits received transportal SIRT with Yttrium 90 resin microspheres of the cranial lobes with different activities (0.3, 0.6 and 1.2 GBq), corresponding to predicted absorbed radiation dose of 200, 400 and 800 Gy, respectively. Another group received non-loaded microspheres (sham group). Cranial and caudal lobes volumes were assessed using CT volumetry before, 15 and 30 days after SIRT. Liver biochemistry, histopathology and gene expression were evaluated. Four untreated rabbits were used as controls for gene expression studies. All animals receiving 1.2 GBq were euthanized due to clinical deterioration. Cranial SIRT with 0.6 GBq induced caudal lobe hypertrophy after 15 days (median increase 34% -ns-) but produced significant toxicity. Cranial SIRT with 0.3 GBq induced caudal lobe hypertrophy after 30 days (median increase 82%, p = 0.04). No volumetric changes were detected in sham group. Transient increase in serum transaminases was detected in all treated groups returning to normal values at 15 days. There was dose-dependent liver dysfunction with bilirubin elevation and albumin decrease. Histologically, 1.2 GBq group developed permanent severe liver damage with massive necrosis, 0.6 and 0.3 GBq groups developed moderate damage with inflammation and portal fibrosis at 15 days, partially recovering at 30 days. There was no difference in the expression of hepatocyte function and differentiation genes between 0.3 GBq and control groups. Cranial SIRT with 0.3 GBq of 90Y resin microspheres in rabbits is a reliable animal model to analyse the atrophy-hypertrophy complex and liver damage without toxicity.


Subject(s)
Atrophy/pathology , Hypertrophy/pathology , Liver Diseases/pathology , Liver/pathology , Yttrium Radioisotopes/toxicity , Animals , Atrophy/etiology , Female , Hypertrophy/etiology , Liver/radiation effects , Liver Diseases/etiology , Rabbits
2.
J Vasc Interv Radiol ; 32(6): 836-842.e2, 2021 06.
Article in English | MEDLINE | ID: mdl-33689835

ABSTRACT

PURPOSE: To compare hepatic hypertrophy in the contralateral lobe achieved by unilobar transarterial radioembolization (TARE) versus portal vein embolization (PVE) in a swine model. METHODS: After an escalation study to determine the optimum dose to achieve hypertrophy after unilobar TARE in 4 animals, 16 pigs were treated by TARE (yttrium-90 resin microspheres) or PVE (lipiodol/n-butyl cyanoacrylate). Liver volume was calculated based on CT before treatment and during 6 months of follow-up. Independent t-test (P < .05) was used to compare hypertrophy. The relationship between hypertrophy after TARE and absorbed dose was calculated using the Pearson correlation. RESULTS: At 2 and 4 weeks after treatment, a significantly higher degree of future liver remnant hypertrophy was observed in the PVE group versus the TARE group, with a median volume gain of 31% (interquartile range [IQR]: 16%-66%) for PVE versus 23% (IQR: 6%-36%) for TARE after 2 weeks and 51% (IQR: 47%-69%) for PVE versus 29% (IQR: 20%-50%) for TARE after 4 weeks. After 3 and 6 months, hypertrophy converged without a statistically significant difference, with a volume gain of 103% (IQR: 86%-119%) for PVE versus 82% (IQR: 70%-96%) for TARE after 3 months and 115% (IQR: 70%-46%) for PVE versus 86% (IQR: 58%-111%) for TARE after 6 months. A strong correlation was observed between radiation dose (median 162 Gy, IQR: 139-175) and hypertrophy. CONCLUSIONS: PVE resulted in rapid hypertrophy within 1 month of the procedure, followed by a plateau, whereas TARE resulted in comparable hypertrophy by 3-6 months. TARE-induced hypertrophy correlated with radiation absorbed dose.


Subject(s)
Embolization, Therapeutic , Enbucrilate/administration & dosage , Ethiodized Oil/administration & dosage , Hepatic Artery , Liver Regeneration , Liver/blood supply , Portal Vein , Radiopharmaceuticals/administration & dosage , Yttrium Radioisotopes/administration & dosage , Animals , Embolization, Therapeutic/adverse effects , Enbucrilate/toxicity , Ethiodized Oil/toxicity , Female , Hepatic Artery/diagnostic imaging , Hypertrophy , Injections, Intra-Arterial , Injections, Intravenous , Liver/diagnostic imaging , Liver/pathology , Models, Animal , Portal Vein/diagnostic imaging , Radiopharmaceuticals/adverse effects , Swine , Swine, Miniature , Time Factors , Yttrium Radioisotopes/toxicity
3.
J Biomed Mater Res B Appl Biomater ; 108(6): 2396-2406, 2020 08.
Article in English | MEDLINE | ID: mdl-32017405

ABSTRACT

Luminescent lanthanide downconversion nanoparticles (DCNPs) provide a combination of high luminescence intensity, sharp emission peaks with narrow bandwidth and a large Stokes' shift, leading to high-performance biomedical applications mainly for imaging. The purpose of this study is to present a nanotoxicological study of DCNPs Y2 O3 codoped with Eu3+ and functionalized with folic acid (FA). These assessments include cytotoxicity, genotoxicity, hemocompatibility, and in vitro inflammatory studies. We demonstrated by flow cytometry and confocal microscope the internalization of FA-DCNPs in breast cancer and melanoma cells. They were synthesized by sol-gel method and coated with a thin silica shell to make them biocompatible; also they were functionalized with amino groups and FA ligands that bind to the folate receptors (FR) located on the surface of the cancer cells studied. This functionalization enables the DCNPs to be internalized into the cancer cells via endocytosis by the conjugation FA-FR. The DCNPs were characterized with transmission electron microscope, Fourier transform infrared spectroscopy and photoluminescence. The nanotoxicological assessments demonstrated that both nanoparticles (bare and functionalized) are no cytotoxic and no genotoxic at the tested concentrations (0.01-20 µg/mL) in three cell lines (breast, skin cancer, and osteoblasts). Also they are hemocompatible and do not exert nitric oxide production in vitro by macrophages. The FA-DCNPs were clearly localized into the cell cytoplasm with bright red luminescence. Thus, herein we present a complete nanotoxicological study of FA-DCNPs Y2 O3 codoped with Eu3+ and we conclude that these nanoparticles are biocompatible and can be further used for cancer cells bioimaging.


Subject(s)
Aluminum Oxide/toxicity , Diagnostic Imaging/methods , Europium/chemistry , Folic Acid/chemistry , Luminescent Agents/chemistry , Nanoparticles/toxicity , Nanostructures/toxicity , Neoplasms/pathology , Animals , Biocompatible Materials , Carcinogenicity Tests , Cell Line, Tumor , Cell Survival , Folate Receptor 1/metabolism , Humans , Macrophages/drug effects , Mice , Mutagenicity Tests , Nitric Oxide/metabolism , RAW 264.7 Cells , Silicon Dioxide/toxicity , Yttrium Radioisotopes/toxicity
4.
Appl Radiat Isot ; 140: 87-95, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29966938

ABSTRACT

In case of a radiological emergency situation involving e.g. fission of uranium or plutonium, analysis of radioactive strontium will be of importance. The primary radionuclides of interest are 90Sr, its progeny 90Y and 89Sr. A few days following an event, 89Sr will be the predominant radioisotope of strontium. Most methods found in the literature are valid and applicable when measuring 90Sr, but when samples contain both 89Sr/90Sr interference problematics arise. How these interferences are dealt with will have an effect on the uncertainty of the 90Sr determination. This work aims at evaluating three measurement approaches, all mentioned in the literature, with respect to the measurement uncertainty when determining 90Sr in an emergency preparedness situation and to propose a suitable measurement strategy.


Subject(s)
Radiation Monitoring/methods , Strontium Radioisotopes/analysis , Civil Defense , Humans , Mass Spectrometry , Nuclear Weapons , Radioactive Hazard Release , Scintillation Counting/methods , Strontium Radioisotopes/toxicity , Uncertainty , Yttrium Radioisotopes/analysis , Yttrium Radioisotopes/toxicity
5.
Cancer Biother Radiopharm ; 24(6): 659-65, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20025545

ABSTRACT

PURPOSE: Peptide-receptor radionuclide therapy (PRRT) with somatostatin analogs is an efficient new tool in patients with neuroendocrine tumors, with low risk of toxicity. Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT. METHODS: From May 2005 to May 2007, 16 patients affected by neuroendocrine tumors received PRRT with (90)Y-DOTATOC (9), (177)Lu-DOTATATE (5), or both (2). Absolute count, percentage of leukocytes and lymphocytes, and lymphoid subsets (B, T, and NK) were tested at baseline and until 90 days after treatment. RESULTS: A significant lymphoid toxicity (G2-3), mainly affecting B-cells, was observed. It was particularly evident after (90)Y-DOTATOC. Toxicity resulted in being transient and resolved completely at the end of the follow-up (90 days). CONCLUSION: Lymphocyte toxicity in PRRT is mainly due to the selective targeting on B-cells. The relative sparing of T-lymphocytes could explain the absence of clinical side-effects in these patients, such as increased risk of infections. These findings open interesting perspectives in the treatment of B-cell lymphoproliferative disorders.


Subject(s)
Lymphocytes/radiation effects , Octreotide/analogs & derivatives , Organometallic Compounds/toxicity , Organometallic Compounds/therapeutic use , Adult , Aged , B-Lymphocytes/pathology , B-Lymphocytes/radiation effects , Colonic Neoplasms/pathology , Colonic Neoplasms/radiotherapy , Duodenal Neoplasms/pathology , Duodenal Neoplasms/radiotherapy , Female , Humans , Ileal Neoplasms/pathology , Ileal Neoplasms/radiotherapy , Lung Neoplasms/pathology , Lung Neoplasms/radiotherapy , Lutetium/therapeutic use , Lutetium/toxicity , Lymphocyte Count , Lymphocytes/pathology , Male , Middle Aged , Octreotide/therapeutic use , Octreotide/toxicity , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/radiotherapy , Yttrium Radioisotopes/therapeutic use , Yttrium Radioisotopes/toxicity
6.
Leuk Lymphoma ; 49(9): 1702-9, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18661405

ABSTRACT

Radioimmunotherapy with Yttrium-90 ((90)Y) ibritumomab tiuxetan (IT) has been shown to be effective in systemic B-cell lymphomas. We conducted a pilot study to evaluate the outcome and assess complications of (90)Y IT therapy in patients with primary cutaneous B-cell lymphomas (PCBCL). Ten patients, all but one, with relapsed PCBCL were included and treated with rituximab (250 mg m(-2)/body surface) on days 1 and 8 followed by a single dose of (90)Y IT (11-15 MBq kg(-1)). The overall response rate was 100%. The complete response rate was 100%. The median time to relapse was 12 months. Ongoing remissions were achieved in four patients (median follow-up 19 months). Transient and reversible myelosuppression (grade 3-4) was the most frequent adverse event. Radioimmunotherapy with (90)Y IT is an effective treatment in relapsed primary cutaneous follicle centre lymphomas and diffuse large B-cell lymphoma leg-type. Further investigations in controlled randomised clinical trials evaluating the role of (90)Y IT versus rituximab in PCBCL are needed.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Lymphoma, B-Cell/radiotherapy , Radioimmunotherapy/methods , Skin Neoplasms/radiotherapy , Yttrium Radioisotopes/therapeutic use , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Male , Middle Aged , Pilot Projects , Radioimmunotherapy/adverse effects , Remission Induction , Salvage Therapy , Treatment Outcome , Yttrium Radioisotopes/toxicity
7.
Blood ; 110(1): 54-8, 2007 Jul 01.
Article in English | MEDLINE | ID: mdl-17387223

ABSTRACT

A prospective, multicenter, nonrandomized phase 2 trial was conducted to evaluate the efficacy and safety of a single dose of yttrium-90 ((90)Y) ibritumomab tiuxetan in elderly patients in first relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) ineligible for stem-cell transplantation. Patients had been previously treated with chemotherapy (group A, n = 76) or chemotherapy plus rituximab (group B, n = 28). Patients in group A were further divided into patients in whom induction therapy had failed (stratum AI, n = 33) and patients who had relapsed after achieving complete response (CR; stratum AII, n = 43). The overall response rate (ORR) was 52% and 53% in strata AI and AII, respectively, and 19% in group B, with CR/CRu rates of 24%, 39.5%, and 12%, respectively. Median progression-free survival was 5.9 months and 3.5 months in strata AI and AII, respectively, and 1.6 months in group B. Median overall survival was 21.4, 22.4, and 4.6 months in stratum AI, stratum AII, and group B, respectively. Two patients died from thrombocytopenic cerebral bleeding following administration of therapy. Nonhematologic adverse events were mild to moderate. (90)Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Lymphoma, B-Cell/radiotherapy , Lymphoma, Large B-Cell, Diffuse/radiotherapy , Salvage Therapy/methods , Yttrium Radioisotopes/therapeutic use , Aged , Aged, 80 and over , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/toxicity , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cerebral Hemorrhage/chemically induced , Female , Humans , Lymphoma, B-Cell/complications , Lymphoma, B-Cell/mortality , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Recurrence , Remission Induction , Rituximab , Survival Analysis , Yttrium Radioisotopes/administration & dosage , Yttrium Radioisotopes/toxicity
8.
Ann Rheum Dis ; 65(10): 1384-9, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16644786

ABSTRACT

BACKGROUND: It was recently shown that radiation synovectomy with yttrium-90 (90Y) and glucocorticoids is not superior to intra-articular glucocorticoids alone in the treatment of persistent gonarthritis. In that study, it seemed that in patients treated by radiation synovectomy, progression of radiographic joint damage occurred. OBJECTIVE: To test in vitro the direct effects of radiation synovectomy with 90Y on human cartilage. METHODS: Human cartilage tissue was exposed to 90Y, glucocorticoids or the combination. 1:2000 to 1:20 dilutions of the clinical dose of 5 mCi/ml 90Y and 20 mg/ml glucocorticoids were used. After a 4-day exposure and a subsequent 12-day recovery period, proteoglycan synthesis, proteoglycan release and proteoglycan content were measured. In addition, human synovial tissue was cultured for 4 days with 90Y or glucocorticoids. Culture supernatants were analysed for cartilage-destructive activity. RESULTS: 90Y, glucocorticoids and the combination inhibited proteoglycan synthesis considerably and dose dependently, an effect that sustained for at least 12 days. Proteoglycan release was transiently increased by 90Y, an effect that was not changed by addition of glucocorticoids, which had no effect on its own. Proteoglycan content was eventually adversely affected by 90Y, an effect hardly influenced by glucocorticoids. Neither 90Y nor glucocorticoids changed the cartilage-destructive properties of synovial tissue. CONCLUSIONS: 90Y, but not glucocorticoids, has direct harmful effects on cartilage in vitro. Indirect beneficial effects of 90Y via inhibition of cartilage-destructive properties of synovial tissue could not be shown. These observations may explain the possible radiographic joint damage on radiation synovectomy.


Subject(s)
Cartilage, Articular/radiation effects , Glucocorticoids/pharmacology , Radiation Injuries/metabolism , Yttrium Radioisotopes/toxicity , Aged , Cartilage, Articular/drug effects , Cartilage, Articular/metabolism , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Humans , Middle Aged , Proteoglycans/biosynthesis , Proteoglycans/metabolism , Synovial Membrane/drug effects , Synovial Membrane/metabolism , Synovial Membrane/radiation effects , Tissue Culture Techniques
9.
Cancer Sci ; 96(12): 903-10, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16367911

ABSTRACT

We conducted a phase I study to evaluate the safety and efficacy of radioimmunotherapy with yttrium-90-ibritumomab tiuxetan (Y2B8) in Japanese patients with relapsed or refractory indolent B-cell lymphoma. Indium-111-labeled ibritumomab tiuxetan (In2B8; 3.5 or 5 mCi [129.5 or 185 MBq]) was administered on day 1, followed by serial gamma-camera imaging to investigate the distribution of In2B8 in the whole body of patients and to judge the feasibility of Y2B8 administration. Y2B8 with a dose of 0.3 mCi/kg (11.1 MBq/kg) or 0.4 mCi/kg (14.8 MBq/kg) was administered on day 8. Grade 4 neutropenia and grade 3 thrombocytopenia were observed in three of nine of the patients evaluated for safety. Critical toxicities (prolonged thrombocytopenia or severe non-hematological toxicities) were observed in two of six patients in the 0.4 mCi/kg (14.8 MBq/kg) dose group but were not seen in any of the three patients in the 0.3 mCi/kg (11.1 MBq/kg) dose group. The non-hematological toxicities of the nine patients were of grade 2 or less, except in two patients who had been heavily treated previously. They experienced critical toxicities such as infection, diarrhea, hyponatremia and prolonged thrombocytopenia, as well as other frequent grade 2 non-hematological toxicities. Although the pharmacokinetic profiles were similar to those in the US study, one of the two patients was clarified retrospectively as showing abnormal biodistribution of In2B8 in the bone marrow, as judged by an independent third party panel of radiologists. Five of the 10 participants achieved complete responses or unconfirmed complete responses and two partial responses. In conclusion, the recommended dose of Y2B8 for the subsequent phase II study for Japanese patients is 0.4 mCi/kg (14.8 MBq/kg). This dose of radioimmunotherapy was feasible when patients with altered biodistribution of In2B8 were excluded, and it was highly effective. (Cancer Sci 2005; 96: 903-910).


Subject(s)
Antibodies, Monoclonal/toxicity , Lymphoma, B-Cell/radiotherapy , Radioimmunotherapy/adverse effects , Yttrium Radioisotopes/toxicity , Adult , Aged , Antibodies, Monoclonal/pharmacokinetics , Dose-Response Relationship, Radiation , Female , Humans , Lymphoma, B-Cell/pathology , Male , Middle Aged , Neoplasm Staging , Recurrence , Reproducibility of Results , Tissue Distribution , Yttrium Radioisotopes/pharmacokinetics
10.
Nuklearmedizin ; 44(4): 166-77, 2005.
Article in German | MEDLINE | ID: mdl-16163413

ABSTRACT

90Y-ibritumomab tiuxetan (Zevalin) is currently approved for radioimmunotherapy of patients with relapsed or refractory follicular non-Hodgkin's lymphoma pretreated with rituximab. Future directions are the combined use of 90Y-ibritumomab tiuxetan as part of the initial treatment and as first-line multi-agent therapy of relapsed disease. Current studies investigate patients with other than follicular indolent histologies, e. g. diffuse large cell lymphoma. Labelling of 90Y ibritumomab tiuxetan is a safe procedure, the radiochemical purity is not disturbed by a higher room temperature or by metallic impurity. Quality control is recommended by thin layer chromatography (TLC), strips >15 cm are favourable. TLC cannot distinguish between the correctly radiolabelled antibodies and radiocolloid impurity. If necessary, additional HPLC should be performed. Radiocolloid impurities are absorbed to the solid phase and do not reach the eluate. If the radiochemical purity test is insufficient (<95%), the additional cleaning using EconoPac 10 DG columns (Biorad, Hercules, CA, USA) is a reliable procedure to reduce the percentage of free radionuclide. However, this procedure is not part of the approval.


Subject(s)
Radioimmunotherapy/methods , Yttrium Radioisotopes/standards , Anemia/diagnostic imaging , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal/toxicity , Chromatography, High Pressure Liquid , Humans , Lymphoma/radiotherapy , Neutropenia/diagnostic imaging , Quality Control , Radiation Protection , Radionuclide Imaging , Thrombocytopenia/diagnostic imaging , Yttrium Radioisotopes/therapeutic use , Yttrium Radioisotopes/toxicity
11.
Regul Toxicol Pharmacol ; 40(3): 207-18, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15546676

ABSTRACT

A synchronous evaluation was performed, using a quick in vivo [2-(14)C]thymidine labeling method, of the toxico- and pharmaco-dynamics of a given dose of yttrium-90 (90Y) at a given time after injection to nude BALB/c mice loaded with 10(7) HuO9 cells. Quantitative data were 14C-microautoradiographs of the liver lobule, intestinal crypts, epiphysial growth plate, secondary ossification center containing pluripotent stem cells, perifollicular zone containing unipotent stem cells in the spleen, and plasmacytoma cells in the osteogenic sarcoma in each mouse following a 10-min labeling with 14C at 0.5, 6, and 24 h after i.v. injection of 90Y. Results show that the cell proliferation rate of the stem cells in respective tissues was markedly suppressed, dependent on time after dosing and the dose of 90Y; 3.7, 37, 370, 3700, and 37,000 kBq per mouse (25 g). In addition to the above, the sensitivity of the proliferation rate was dependent on amitosis or mitosis and the AUC value of 90Y-concentration at specific locations of the cells in the mouse body. The most sensitive cells were the plasmacytoma cells, followed by the pluripotent and unipotent stem cells, the intestinal crypts, epiphysial growth plate, and liver cells.


Subject(s)
Autoradiography/methods , Yttrium Radioisotopes/pharmacology , Yttrium Radioisotopes/toxicity , Animals , Area Under Curve , Bone Marrow/diagnostic imaging , Bone Neoplasms/diagnostic imaging , Cell Line, Tumor , Cell Nucleus/ultrastructure , Epiphyses/diagnostic imaging , Half-Life , Humans , Isotope Labeling , Jejunum/diagnostic imaging , Mice , Mice, Inbred BALB C , Mice, Nude , Mitosis/drug effects , Osteosarcoma/diagnostic imaging , Plasmacytoma/diagnostic imaging , Radionuclide Imaging , Spleen/diagnostic imaging , Stem Cells/diagnostic imaging , Thymidine , Tissue Distribution , Tissue Fixation
12.
Cancer Biother Radiopharm ; 19(1): 11-23, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15068607

ABSTRACT

Studies were performed to determine the suitability of using two different anti-CD19 monoclonal antibodies to deliver the high energy beta-particle emitting isotope 90Y to B-cell lymphoma grown as flank tumors in athymic nude mice. The antibodies BU12 and HD37, both of the IgG1 subclass, recognize CD19, an internalizing B-lineage-specific membrane glycoprotein and member of the Ig supergene family. The antibodies were readily labeled with 90Y using the highly stable chelate, 1B4M-MX-DTPA. The radioimmunoconjugates selectively bound to the CD19 expressing B cell line Daudi, but not to CD19 negative control cells. Significantly more 90Y anti-CD19 bound to Daudi tumors growing in nude mice than did a control non-binding antibody (p = 0.001). The biodistribution data correlated with an anti-tumor effect. Anti-tumor activity was dose dependent and the best results were observed in mice receiving a single dose of approximately 300 uCi. The anti-CD19 antibody had significantly better anti-tumor activity as compared to a control 90Y-labeled antibody and most mice survived over 119 days with no evidence of tumor (p < 0.003). Histology studies showed no significant injury to the kidney, liver, or small intestine. Because radiolabeled anti-CD19 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data support the use of 90Y anti-CD19 antibodies in treating B-cell malignancies.


Subject(s)
Antibodies, Monoclonal/immunology , Antigens, CD19/immunology , Burkitt Lymphoma/immunology , Burkitt Lymphoma/radiotherapy , Radioimmunotherapy/methods , Yttrium Radioisotopes/toxicity , Yttrium Radioisotopes/therapeutic use , Animals , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal/therapeutic use , Antibody Affinity , Burkitt Lymphoma/pathology , Cell Line, Tumor , Humans , Indium Radioisotopes , Mice , Mice, Nude , Protein Binding , Radiopharmaceuticals/pharmacokinetics , Radiopharmaceuticals/therapeutic use , Radiopharmaceuticals/toxicity , Tissue Distribution , Yttrium Radioisotopes/pharmacokinetics
13.
Cancer Biother Radiopharm ; 19(1): 65-71, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15068613

ABSTRACT

UNLABELLED: Metastatic medullary thyroid cancer (MTC) shows a progressive course. Surgery is the only curative treatment. In advanced disease, chemo- and radiotherapy show poor results. Newly developed somatostatin analogue [DOTA0,Tyr3]octreotide (DOTATOC) labeled to 90Y is administered in patients with endocrine tumors expressing somatostatin receptors, like MTC. Preliminary studies demonstrated that 90Y-DOTATOC could be safely administered, resulting in objective responses in 27% of patients. AIMS: To evaluate the efficacy of 90Y-DOTATOC therapy in metastatic MTC patients with positive OctreoScan, progressing after conventional treatments. Twenty-one patients were retrospectively evaluated after therapy, receiving 7.5-19.2 GBq in 2-8 cycles. RESULTS: Two patients (10%) obtained a complete response (CR), as evaluated by CT, MRI and/or ultrasound, while a stabilization of disease (SD) was observed in 12 patients (57%); seven patients (33%) did not respond to therapy. The duration of the response ranged between 3-40 months. Using biochemical parameters (calcitonin and CEA), a complete response was observed in one patient (5%), while partial response in five patients (24%) and stabilization in three patients (14%). Twelve patients had progression (57%). Complete responses were observed in patients with lower tumor burden and calcitonin values at the time of the enrollment. CONCLUSIONS: This retrospective analysis is consistent with the literature, regarding a low response rate in medullary thyroid cancers treated with 90Y-DOTATOC. Patients with smaller tumors and higher uptake of the radiopeptide tended to respond better. Studies with 90Y-DOTATOC administered in earlier phases of the disease will help to evaluate the ability of this treatment to enhance survival. New more specific peptides and new isotopes will also represent the key of a better treatment of MTC.


Subject(s)
Carcinoma, Medullary/radiotherapy , Octreotide/analogs & derivatives , Octreotide/therapeutic use , Radiopharmaceuticals/therapeutic use , Receptors, Somatostatin/metabolism , Thyroid Neoplasms/radiotherapy , Yttrium Radioisotopes/therapeutic use , Adult , Aged , Female , Humans , Male , Middle Aged , Octreotide/adverse effects , Octreotide/pharmacokinetics , Octreotide/toxicity , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/pharmacokinetics , Radiopharmaceuticals/toxicity , Receptors, Somatostatin/antagonists & inhibitors , Retrospective Studies , Somatostatin/analogs & derivatives , Somatostatin/pharmacology , Somatostatin/therapeutic use , Yttrium Radioisotopes/adverse effects , Yttrium Radioisotopes/pharmacokinetics , Yttrium Radioisotopes/toxicity
14.
Blood ; 99(12): 4336-42, 2002 Jun 15.
Article in English | MEDLINE | ID: mdl-12036859

ABSTRACT

Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) have an increased risk of chemotherapy-induced myelosuppression following treatment. The safety and efficacy of radioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32 mCi [1.2 GBq]) was evaluated in 30 patients with mild thrombocytopenia (100-149 x 10(9) platelets/L) who had advanced, relapsed or refractory, low-grade, follicular, or transformed B-cell NHL. The ibritumomab tiuxetan regimen included an infusion of rituximab (250 mg/m(2)) and injection of (111)In ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry evaluation, followed 1 week later with rituximab (250 mg/m(2)) and (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]). Patients (median age, 61 years; 90% stage III/IV at study entry; 83% follicular lymphoma; and 67% with bone marrow involvement) had a median of 2 prior therapy regimens (range, 1-9). Estimated radiation-absorbed doses were well below the study-defined maximum allowable for all 30 patients. With the use of the International Workshop criteria for NHL response assessment, the overall response rate was 83% (37% complete response, 6.7% complete response unconfirmed, and 40% partial response). Kaplan-Meier estimated median time to progression (TTP) was 9.4 months (range, 1.7-24.6). In responders, Kaplan-Meier estimated median TTP was 12.6 months (range, 4.9-24.6), with 35% of data censored. Toxicity was primarily hematologic, transient, and reversible. The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Antineoplastic Agents/administration & dosage , Lymphoma, Non-Hodgkin/therapy , Radioimmunotherapy , Thrombocytopenia/chemically induced , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/pharmacokinetics , Antibodies, Monoclonal/toxicity , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/toxicity , Combined Modality Therapy , Female , Humans , Lymphoma, Non-Hodgkin/complications , Male , Middle Aged , Radiation Dosage , Remission Induction/methods , Salvage Therapy , Thrombocytopenia/prevention & control , Tissue Distribution , Treatment Outcome , Yttrium Radioisotopes/administration & dosage , Yttrium Radioisotopes/pharmacokinetics , Yttrium Radioisotopes/toxicity
15.
Haemophilia ; 7 Suppl 2: 50-3, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11564146

ABSTRACT

One of the best procedures to prevent haem-arthrosis has been radioactive synovectomy (synoviorthesis). Since the first report of radioactive synovectomy in haemophilia of Ahlberg in 1971 [1], many centres adopted this procedure as the one of choice, through fibrosing the synovial membrane, prevent further haemarthrosis. Since 1976 we have performed 104 such radioactive synoviorthesis in 97 patients, age ranging from 6 to 40 years with a mean of 10 years. Sixty-five of these patients were under 12 years of age. The knees were injected in 61 cases, elbow in 26 cases, ankles in 14 cases and shoulders in three cases. The clinical results of this procedure show 80% of excellent results with no further bleeding. In case of failure, a new injection can be given in the same joint at a 6-month interval, or an injection for the same purpose in other joint. One of the criticisms against this method is the possible chromosomal damage induced by the radioactive material. In our centre, four studies have been carried out in order to see whether these changes, when they occur, are everlasting; all have demonstrated that chromosomal changes are reversible. The radioactive material used in the two first studies was Gold-189 (189Au). In 1978, 354 metaphases were studied with 61 ruptures, 17.23% (nonpremalign) and six structural changes, considered premalign (1.69%). Any number below 2% is considered not to be dangerous. A further study was done in 1982, in the same group of patients with a result of 21 ruptures (3.34%) and no structural changes. This demonstrated that the possible premalign changes disappeared with time. A third study was performed in a series of 13 patients that sustained radioactive synoviorthesis with Rhenium-186 (186Re) in November 1991. For comparison, we carried out a chromosomal study just before and 6 months after the radioactive material injection. The results confirmed that changes that could be linked to the radiation, appeared equally in nonirradiated patients, and those changes due to the radiation disappear with time, never reaching the dangerous zone of 2%. In the group treated with 186Re we studied an additional number of 130 metaphases with identical results and no structural changes. In a study on patients where 90Y was the radiocolloid, no premalign change was found before or after the synoviorthesis. It seems, in view of these results, that radioactive synovectomy is safe and gives great benefits to the haemophilic patients.


Subject(s)
Hemophilia A/complications , Radioisotopes/administration & dosage , Radioisotopes/toxicity , Synovitis/drug therapy , Adolescent , Adult , Child , Chromosome Aberrations/radiation effects , Cytogenetic Analysis , Follow-Up Studies , Gold Radioisotopes/administration & dosage , Gold Radioisotopes/therapeutic use , Gold Radioisotopes/toxicity , Hemarthrosis/complications , Hemarthrosis/drug therapy , Hemarthrosis/etiology , Hemophilia A/pathology , Hemophilia A/therapy , Humans , Injections, Intra-Articular , Radioisotopes/therapeutic use , Rhenium/administration & dosage , Rhenium/therapeutic use , Rhenium/toxicity , Safety , Synovitis/etiology , Synovitis/pathology , Treatment Outcome , Yttrium Radioisotopes/administration & dosage , Yttrium Radioisotopes/therapeutic use , Yttrium Radioisotopes/toxicity
16.
Proc Natl Acad Sci U S A ; 97(4): 1802-7, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10677537

ABSTRACT

A covalent conjugate (NR-LU-10/SA) was prepared between streptavidin (SA) and NR-LU-10, a mAb that binds an antigen expressed on the surface of most human carcinomas. NR-LU-10/SA was injected into nude mice bearing human tumor xenografts. Injection of biotinylated galactosyl-human serum albumin reduced the circulating levels of conjugate by 95%. Subsequent administration of (90)Y-1,4,7, 10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-biotin achieved peak uptake at the tumor within 2 hr while >80% of the radioactivity was eliminated in the urine. A single dose of 600-800 microCi of (90)Y-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-biotin produced cures in 10/10 mice with established (>200 mm(3)) s.c. human small cell lung or colon cancer xenografts and 8/10 cures in mice with human breast cancer xenografts without significant toxicity.


Subject(s)
Carcinoma/metabolism , Colonic Neoplasms/drug therapy , Neoplasm Transplantation , Transplantation, Heterologous , Yttrium Radioisotopes , Yttrium Radioisotopes/therapeutic use , Animals , Antibodies, Monoclonal , Antigens, Neoplasm/immunology , Antineoplastic Agents/blood , Antineoplastic Agents/pharmacology , Cell Adhesion Molecules/immunology , Chelating Agents/chemistry , Colonic Neoplasms/immunology , Epithelial Cell Adhesion Molecule , Heterocyclic Compounds, 1-Ring/chemistry , Humans , Mice , Mice, Nude , Molecular Structure , Radioimmunotherapy/methods , Radiopharmaceuticals/therapeutic use , Radiopharmaceuticals/toxicity , Yttrium Radioisotopes/toxicity
17.
Eur J Nucl Med ; 26(11): 1439-47, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10552085

ABSTRACT

In a pilot study, DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC), which can be labelled with the beta-emitting radioisotope yttrium-90, has recently been used for the treatment of patients with advanced somatostatin receptor-positive tumours who had no other treatment option. The aim of the present study was to elucidate the therapeutic potential of (90)Y-DOTATOC in a larger number of patients employing a standardized treatment protocol. Careful attention was paid to any side-effects (renal and/or haematological toxicity). Of 44 patients with advanced somatostatin receptor-positive tumours of different histology, 29 could be included in the study. The 15 patients who were excluded from the study protocol were assigned to our institution for purely compassionate reasons. The 29 patients who were included received four or more single doses of (90)Y-DOTATOC with ascending activity at intervals of approximately 6 weeks (cumulative dose 6120+/-1347 MBq/m(2)) with the aim of performing an intra-patient dose escalation study. In total, 127 single treatments were given. In eight of these 127 single treatments, total doses of > or = 3700 MBq were administered. In an effort to prevent renal toxicity, two patients received Hartmann-Hepa 8% solution during all therapy cycles, while 13 patients did so during some but not all therapy cycles; in 14 patients no solution was administered during the therapy cycles. The treatment was monitored by computed tomography and indium-111 DOTATOC scintigraphy. Blood parameters were controlled weekly, while tumour markers and liver enzymes were controlled 6-weekly. Of the 29 patients, 24 patients showed no severe renal or haematological toxicity (toxicity < or = grade 2 according to the National Cancer Institute grading criteria). These 24 patients received a cumulative dose of < or = 7400 MBq/m(2). Five patients developed renal and/or haematological toxicity. All of these five patients received a cumulative dose of >7400 MBq/m(2) and had received no Hartmann-Hepa 8% solution during the therapy cycles. Four of the five patients developed renal toxicity; two of these patients showed stable renal insufficiency and two require haemodialysis. Two of the five patients exhibited anaemia (both grade 3) and thrombopenia (grade 2 and 4, respectively). To date, 20 of the 29 patients have shown a disease stabilization, two a partial remission, four a reduction of tumour mass <50% and three a progression of tumour growth. (90)Y-DOTATOC could be a powerful and promising new therapeutic agent for anti-cancer treatment - at least in terms of an adjuvant starting point of the disease. However, problems with toxicity have to be solved. Evaluation of the effect of amino acid infusions (e.g. Hartmann-Hepa 8% solution) during (90)Y-DOTATOC treatments with the aim of reducing renal toxicity is ongoing.


Subject(s)
Neoplasms/radiotherapy , Octreotide/analogs & derivatives , Radiopharmaceuticals/therapeutic use , Yttrium Radioisotopes/therapeutic use , Adult , Aged , Female , Humans , Indium Radioisotopes , Male , Middle Aged , Neoplasms/diagnostic imaging , Octreotide/therapeutic use , Octreotide/toxicity , Radionuclide Imaging , Radiopharmaceuticals/toxicity , Receptors, Somatostatin/analysis , Yttrium Radioisotopes/toxicity
18.
Radiat Res ; 150(2): 212-26, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9692367

ABSTRACT

This study was conducted in dogs to determine the toxicity of inhaled 91YCl3, which is of interest because 91Y is a fission-product radionuclide that is abundant in a reactor inventory after sustained operation. Yttrium-91 has a short half-life, 59 days, and decays with the emission of beta particles and low-yield gamma rays. The study was conducted in 58 beagle dogs with equal numbers of males and females. Forty-six dogs inhaled the 91YCl3 aerosol, while 12 served as controls. Four exposure levels were used. To determine the long-term retained burden (LTRB) of 91Y, each dog was periodically whole-body counted and its excreta were analyzed radiochemically. Over time, the 91Y transferred from the lung primarily to the skeleton and liver. The dogs were observed over their life spans for biological effects. Fatal hematological dyscrasia occurred from 12 to 33 days after exposure in the dogs with the highest LTRBs. Bone-associated tumors of the nasal and oral mucosae occurred in 5 dogs from 2000 to 5800 days after they inhaled the 91YCl3 aerosols. Five dogs died with malignant lung tumors and 2 dogs with malignant liver tumors. The results of this study were compared to those from similar studies in beagles that inhaled 90SrCl2 or 144CeCl3 or were injected with 137CsCl. The comparison showed that the biological effects in each study were clearly dependent on the cumulative doses to critical organs.


Subject(s)
Yttrium Radioisotopes/toxicity , Administration, Inhalation , Animals , Blood Cells/radiation effects , Cause of Death , Dogs , Female , Liver Neoplasms, Experimental/etiology , Lung Neoplasms/etiology , Male , Neoplasms, Radiation-Induced , Radiation Dosage , Tissue Distribution , Yttrium Radioisotopes/administration & dosage , Yttrium Radioisotopes/pharmacokinetics
19.
Invest Radiol ; 30(12): 716-23, 1995 Dec.
Article in English | MEDLINE | ID: mdl-8748185

ABSTRACT

RATIONALE AND OBJECTIVES: To test the selectivity of tissue damage in radioembolization, the authors performed an experimental study using superselective administration of yttrium-90 particles to deliver up to 100 Gy to the porcine kidney. Patterns and severity of damage in test organs were compared with controls, and the feasibility of this model is discussed. METHODS: Eight sows were included in the study. Bio-Rex 70 particles were applied via selective catheterization of the renal artery. Four pigs received inactive particles and four pigs received active particles. Organ distribution and shunting of yttrium-90 were determined, and kidney damage patterns were histologically analyzed. RESULTS AND CONCLUSIONS: The model demonstrates that yttrium-90-labeled resin particles can superselectively be applied. Retention of beta activity in the target organ was more than 95%. In addition to tissue shrinkage from mechanical obstruction, considerable damage ensued mainly by radiation-induced arterial necrosis and arteritis.


Subject(s)
Embolization, Therapeutic , Kidney/radiation effects , Radiation Injuries, Experimental/pathology , Yttrium Radioisotopes/toxicity , Animals , Dose-Response Relationship, Radiation , Female , Infarction/pathology , Kidney/blood supply , Kidney/pathology , Microspheres , Swine , Tissue Distribution , Yttrium Radioisotopes/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...